Future Science Group
Browse
FON-2021-0899 Journal Article Infographic.pdf (973 kB)

FON-2021-0899 Infographic – Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003

Download (973 kB)
figure
posted on 2021-11-16, 11:57 authored by Tae Won Kim, Julien Taieb, Ellen B Gurary, Nati Lerman, Karen Cui, Takayuki Yoshino
Infographic: Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003

Funding

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., NJ, USA, and AstraZeneca

History

Usage metrics

    Future Oncology

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC